Cargando…
Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570
The proteasome is a validated target of cancer therapeutics. Inhibition of proteasome activity results in the activation of the unfolded protein response (UPR) characterized by phosphorylation of eukaryotic initiation factor 2α (eIF2α), global translational arrest, and increased expression of the pr...
Autores principales: | Pellegrini, Paola, Selvaraju, Karthik, Faustini, Elena, Mofers, Arjan, Zhang, Xiaonan, Ternerot, Jens, Schubert, Alice, Linder, Stig, D′Arcy, Pádraig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369842/ https://www.ncbi.nlm.nih.gov/pubmed/32635430 http://dx.doi.org/10.3390/ijms21134757 |
Ejemplares similares
-
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
por: Wang, Xin, et al.
Publicado: (2016) -
Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
por: Wang, Xin, et al.
Publicado: (2016) -
Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System
por: Selvaraju, Karthik, et al.
Publicado: (2021) -
Proteasome-associated deubiquitinases and cancer
por: Mofers, Arjan, et al.
Publicado: (2017) -
Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15
por: Mofers, Arjan, et al.
Publicado: (2019)